FILTER

FILTERED INTERVIEW RESULTS

Mining
Canada

Ryan McEachern

MANAGING DIRECTOR, MSTA CANADA
MSTA sets out the currant priorities of the Canadian mining service and supply sector.
Mining
Canada

Ed Santamaria

PRESIDENT AND CEO, NORMET GROUP
Normet Canada introduces some of the innovations that it is bringing to the underground mining market.
Mining
Canada

Renaud Adams

PRESIDENT & CEO, NEW GOLD INC.
New Gold updates GBR on progress at its Rainy River and New Afton mines
Mining
Canada

Louise Pearce

GLOBAL MINING DIRECTOR, ERM
ERM works with clients all over the world, helping them to progress their ESG priorities and create innovative solutions to sustainability challenges.
Mining
Canada

Eric Smith

MANAGING DIRECTOR, CEMENTATION AMERICAS
"We need to maintain a measured approach on the new technologies we incorporate given the cost, but will continue to transform our culture and how we perform work."
Mining
Canada

Emily Thorn Corthay

FOUNDER & CEO, THORN ASSOCIATES
"We need to ensure that greenhouse gas data, which is mostly energy data, is up to the same level of rigor and verification as financial data."
Mining
Canada

Giuseppe Campanelli

PRESIDENT OF NORTH AND CENTRAL AMERICA, METSO OUTOTEC
Metso Outotec updates GBR on its North American operations.
Mining
Canada

Vance White

PRESIDENT AND CEO, NOBLE MINERAL EXPLORATION INC.
Noble Mineral Exploration is a Canadian Project Generator.
Mining
Canada

Don Bertrand

GENERAL SALES MANAGER, X-GLO NORTH AMERICA INC.
"One of our most recent developments is our partnership with FiComm Technologies to design and develop a Visual Alert Control System (VACS)."
Mining
Canada

James Tworek

CEO, ELEMENT79 GOLD
"The acquisition of Plutus Gold and the Snowbird property is part of our extensive M&A strategy and is only the first of several potential opportunities."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL